Valeant Pharmaceuticals International (VRX) Rating Increased to Strong-Buy at Vetr

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) was upgraded by equities research analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Tuesday. The firm presently has a $19.72 price objective on the specialty pharmaceutical company’s stock. Vetr‘s price objective points to a potential upside of 17.03% from the company’s current price.

A number of other brokerages also recently weighed in on VRX. Deutsche Bank set a $18.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Sunday. Scotiabank increased their price target on shares of Valeant Pharmaceuticals International from $14.00 to $16.00 and gave the company a “sector perform” rating in a research report on Wednesday, August 9th. HC Wainwright set a $17.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $14.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “sell” rating in a research report on Wednesday, August 9th. Finally, BMO Capital Markets raised their target price on shares of Valeant Pharmaceuticals International from $16.00 to $17.00 and gave the stock a “market perform” rating in a report on Monday, November 13th. Five research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $17.46.

Shares of Valeant Pharmaceuticals International (VRX) opened at $16.85 on Tuesday. The firm has a market cap of $6,096.87, a P/E ratio of 2.84, a P/E/G ratio of 0.48 and a beta of -0.22. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $18.25.

In related news, Director John Paulson bought 344,216 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were purchased at an average cost of $14.40 per share, for a total transaction of $4,956,710.40. Following the acquisition, the director now owns 94,559 shares of the company’s stock, valued at approximately $1,361,649.60. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 5.87% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Riggs Asset Managment Co. Inc. grew its stake in shares of Valeant Pharmaceuticals International by 118.2% during the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after acquiring an additional 4,512 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Valeant Pharmaceuticals International during the 2nd quarter worth approximately $192,000. Harbour Capital Advisors LLC bought a new position in shares of Valeant Pharmaceuticals International during the 3rd quarter worth approximately $224,000. American Century Companies Inc. bought a new position in shares of Valeant Pharmaceuticals International during the 3rd quarter worth approximately $238,000. Finally, Moors & Cabot Inc. grew its stake in shares of Valeant Pharmaceuticals International by 32.3% during the 2nd quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock worth $267,000 after acquiring an additional 3,725 shares in the last quarter. 49.49% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Valeant Pharmaceuticals International (VRX) Rating Increased to Strong-Buy at Vetr” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.com-unik.info/2017/12/07/valeant-pharmaceuticals-international-vrx-rating-increased-to-strong-buy-at-vetr.html.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

What are top analysts saying about Valeant Pharmaceuticals International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Valeant Pharmaceuticals International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit